Romosozumab and Renal Function
- PMID: 35869697
- DOI: 10.1002/jbmr.4645
Romosozumab and Renal Function
Comment on
-
Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease.J Bone Miner Res. 2022 Aug;37(8):1437-1445. doi: 10.1002/jbmr.4563. Epub 2022 May 20. J Bone Miner Res. 2022. PMID: 35466448 Free PMC article. Clinical Trial.
References
-
- Sollas WJ. An experiment to illustrate the mode of flow of a viscous fluid. Q J Geol Soc Lond. 1895;51:361-368.
-
- Masic I, Miokovic M, Muhamedagic B. Evidence based medicine-new approaches and challenges. Acta Inform Med. 2008;16:219-225.
-
- Miller P, Adachi J, Albergaria B-H, et al. Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res 2022;37. [online ahead of print].
-
- Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377:1417-27.
-
- Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375:1532-43.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources